3D Tissue Models Summit on May 06-08, 2025 in Boston, United States

Following the FDA's introduction of the Modernization Act 3.0 and the latest guidance on new approach methods (NAMs), GSK developing a new lung organoid model to empower pulmonary fibrosis research, and Merck acquiring HUB Organoids to enable more effective drug development and reduce reliance on animal testing, it's an exciting time for pharma and biotech to leverage complex in vitro models in drug discovery and development.

Despite this growth, challenges persist in standardizing protocols for model validation, safeguarding model reproducibility while ensuring scalability, and understanding what data regulators will accept.

Built by biopharma-for-biopharma, the 10th 3D Tissue Models Summit returns to unite 'front-line' experts to share practical case studies on validating, improving reproducibility, and interrogating regulatory requirements for complex in vitro models in drug discovery and development.

Join the only intimate, industry-focussed forum to stay abreast on how to confidently harness various complex in vitro models to transform your own discovery and development workflows and empower clinical translatability.

URLs:

Tickets: https://go.evvnt.com/2847780-2?pid=10008

Brochure: https://go.evvnt.com/2847780-3?pid=10008

Time: 9:00 AM - 3:15 PM

Prices:

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + Pre-Conference Workshop Day - Drug Developer Pricing: USD 4297.00,

Conference Only - Academic Pricing: USD 2599.00,

Conference + Pre-Conference Workshop Day - Academic Pricing: USD 3697.00,

Conference Only - Solution Provider Pricing: USD 3699.00,

Conference + Pre-Conference Workshop Day - Solution Provider Pricing: USD 5197.00

Speakers: Anitha Saravanakumar, Scientist II, DMPK, BMS, Jason Ekert, Head of Discovery Translational Technology, UCB, Julie Harney, Senior Principal Scientist, Pfizer, Julien Roth, Senior Scientist, Genentech, Katia Karalis, Executive Director, Formerly Regeneron, Manjunatha Shivannagowda, Principal Scientist, Boehringer Ingelheim, May Freag, Senior Scientist, Takeda, Michelle Recalde, Senior Scientist Cell Biologist, GSK, Muriel Lizé, Associate Director - In Vitro Respiratory Research, Boehringer Ingelheim, Passley Hargrove-Grimes, Program Officer, NIH Tissue Chip Program, NCATS/NIH, Philip Hewitt, Global Head of Early Investigative Toxicology, Merck, Seongmoon Cheong, Senior Scientist, Novo Nordisk, Soumya Mitra, Senior Principal Research Scientist, AbbVie, Sowmya Balasubramanian, Senior Scientist (Biomarker Strategy Lead) Translational Sciences, Astellas, Steffen Dettling, Group Leader, Principal Scientist, Roche, Supreet Agarwal, Discovery Technology, Loxo Oncology at Lilly, Yixiao Cui, Senior Scientist, AbbVie